



The UK's Premier Biopartnering and Investment Conference



Where **great minds** and **smart money** meet **under one roof**

Preliminary Programme

BioTrinity 2010

12 - 14 April
Newbury Racecourse
Newbury
UK

organised by



www.biotrinity.com

Sponsors of BioTrinity 2010*

Platinum Sponsors

(osi) pharmaceuticals



Gold Sponsors

technomark
LIFE SCIENCES

Silver Sponsors

FRY HEATH SPENCE
CHARTERED PATENT & TRADE MARK ATTORNEYS

MERCK & CO., INC.
Whitehouse Station, N.J. U.S.A.

Shire

TEVA

ONTARIO
CANADA

Bronze Sponsors

FOCUS

genzyme

MANCHES

jamescowper
Accountants & Business Advisers

MPI

LTN

pharmanet
Development Group

WORLD COURIER
A SERVICE NO ONE ELSE CAN DELIVER

KBC Peel Hunt

PharmaVentures
Experts in deals and alliances

Investor

Abingworth
investors in life sciences & healthcare

Media & PR Agent

defacto
communications

Project Partners

BIO2BUSINESS
EVENT MANAGEMENT

BioPharm Insight
Leading Insight and Pharmavire Intelligence

BioCentury

MedNous
Critical Insights into the Business of Medical Innovation in Europe

Biotech
東 East

DRUG DISCOVERY
TODAY

tvlsn
where science applies

BioSpectrum
the business of life sciences
ASIA EDITION

Swiss Biotech
Association

European
Biotechnology
NETWORK

nexus

pharmalicensing.com
Open Innovation for the life sciences

NZBIO

*as of 10 February 2010

BIOTRINITY 2010 PRELIMINARY PROGRAMME*

Monday, 12th April 2010																					
18.00	Pre-conference registration and Grand Opening Reception – sponsored by MEPC To be opened by John Penrose MP, Shadow Minister for Business																				
Tuesday, 13th April 2010																					
08.00	Registration and Exhibition open																				
08.50	Welcome and Opening Remarks , Dr Jon Rees, CEO, OBN																				
09.00	VIP address from Lord Howe (invited)																				
09.10	Panel Discussion: As the Investment Landscape Shifts: How to Raise Capital in a Changing World Chaired by Tim Haines, Abingworth Ian Wainwright, Principal Corporate Banking, Piper Jaffray Graziano Seghezzi, Partner, Sofinnova Partners Marco Boorsma, Senior Analyst, Forbion Capital Partners Kassim Mahmood, Principal, Advent Ventures																				
11.00	Panel Discussion: What can be built with Corporate Venture Funds? Chaired by Debbie Harland, SROne Eva Jack, Managing Director, MedImmune Ventures Anker Lundemose, Managing Director, OSI Investment Holding GmbH Graeme Martin, President & CEO, Takeda Research Investment, Inc																				
12.00-17.00	Company Showcase: from Concept to Patient Sponsored by Shire Pharmaceuticals <i>Shire, Introduction and welcome, David Colpman, SVP Business Development</i>																				
	<table border="0"> <tr> <td>Oxagen, Michael Hunter, Director of Drug Discovery</td> <td>BioVex, Colin Love, SVP Development</td> </tr> <tr> <td>Saturn Biosciences, Ray Spencer</td> <td>Summit plc, Steven Lee, CEO</td> </tr> <tr> <td>Syntaxin, Phil Boyd, CFO</td> <td>Synaigen, Richard Marsden, CEO</td> </tr> <tr> <td>Hypha Discovery, Liam Evans, CEO</td> <td>Glycomar, Charlie Bavinton</td> </tr> <tr> <td>Cell Centric, David Knowles, President & CSO</td> <td>Karus Therapeutics, Simon Kerry, CEO</td> </tr> <tr> <td>Pharmatic, Douglas Thompson, CEO</td> <td>Pro-Cure Therapeutics, Micheal McLean, CEO</td> </tr> <tr> <td>BigDNA, John March, CEO & CSO</td> <td>Technomark LS, Allen Hakimi, MD</td> </tr> <tr> <td>Cyprotex, Anthony Baxter, CEO</td> <td>Physiomics, Christophe Chassangnole, COO</td> </tr> <tr> <td>London Genetics, Dominique Kleyn, CEO</td> <td>Oxford Nanopore, Jim McDonald, FD</td> </tr> <tr> <td>OxEpi, Roland Kozlowski, Chairman</td> <td>Inhibox, Paul Davie, CCO</td> </tr> </table>	Oxagen , Michael Hunter, Director of Drug Discovery	BioVex , Colin Love, SVP Development	Saturn Biosciences , Ray Spencer	Summit plc , Steven Lee, CEO	Syntaxin , Phil Boyd, CFO	Synaigen , Richard Marsden, CEO	Hypha Discovery , Liam Evans, CEO	Glycomar , Charlie Bavinton	Cell Centric , David Knowles, President & CSO	Karus Therapeutics , Simon Kerry, CEO	Pharmatic , Douglas Thompson, CEO	Pro-Cure Therapeutics , Micheal McLean, CEO	BigDNA , John March, CEO & CSO	Technomark LS , Allen Hakimi, MD	Cyprotex , Anthony Baxter, CEO	Physiomics , Christophe Chassangnole, COO	London Genetics , Dominique Kleyn, CEO	Oxford Nanopore , Jim McDonald, FD	OxEpi , Roland Kozlowski, Chairman	Inhibox , Paul Davie, CCO
Oxagen , Michael Hunter, Director of Drug Discovery	BioVex , Colin Love, SVP Development																				
Saturn Biosciences , Ray Spencer	Summit plc , Steven Lee, CEO																				
Syntaxin , Phil Boyd, CFO	Synaigen , Richard Marsden, CEO																				
Hypha Discovery , Liam Evans, CEO	Glycomar , Charlie Bavinton																				
Cell Centric , David Knowles, President & CSO	Karus Therapeutics , Simon Kerry, CEO																				
Pharmatic , Douglas Thompson, CEO	Pro-Cure Therapeutics , Micheal McLean, CEO																				
BigDNA , John March, CEO & CSO	Technomark LS , Allen Hakimi, MD																				
Cyprotex , Anthony Baxter, CEO	Physiomics , Christophe Chassangnole, COO																				
London Genetics , Dominique Kleyn, CEO	Oxford Nanopore , Jim McDonald, FD																				
OxEpi , Roland Kozlowski, Chairman	Inhibox , Paul Davie, CCO																				
17.00-18.00	Networking Reception (Sponsored by Shire) <i>All BioTrinity attendees are cordially invited to join us for this Reception</i>																				
19.15	Gala Dinner (Ticket only)																				

Workshops	
Tuesday, 13th April 2010	
12.00–12.30	A Strategy for Skills, Salaries and Shortages SRG Recruitment , hosted by Ena Vieira, Commercial Manager
13.30–14.00	Workshop title to be confirmed James Cowper , hosted by Sue Staunton, Partner
14.00–15.00	Why are solid forms still causing headaches? Almac Group Drug Development Services , hosted by Linda McCausland, Head of Physical Sciences
15.30–16.30	Patents: What's The Point? Fry Heath Spence , hosted by Graham Lock, Partner and Mark Sweetinburgh
16.30–17.00	Available

Wednesday 14th April															
08.00	Registration and Exhibition open														
08.45	Welcome to Day 2 Dr Jon Rees, CEO, OBN														
08.50 – 09.50	Panel Discussion: What's New in Research and License Option and Evaluation Deals? Chaired by Fintan Walton, CEO, PharmaVentures Kate Burt, Director, Commercial Alliances and Transactions at GSK Matthew Walls, CEO, Epistem Tim Sparey, Director of Business Development, Proximagen plc Barry Kenny, CBO, Heptares Therapeutics														
09.50 – 10.30	Panel Discussion: UK Healthcare Market 2010: Is the IPO Window Opening? Chaired by James Steel, KBC Peel Hunt Paul Cuddon, Analyst, KBC Peel Hunt Ian Paling, CEO & Executive Chairman, CellCoTec Ian Garland, CEO, Vernalis plc														
11.00 – 12.00	Panel Discussion: What Pharma Wants: Acquisition and Option Strategies Chaired by Lubor Gaal, BMS Rob Pinnock, Director, Scientific & Academic Liaison Licensing and External Research, Merck David Colpman, Director of Business Development, Shire Christopher Meade, Head of Global Licensing for Respiratory, Boehringer Ingelheim Alan G. Lamont, Director, Science and Technology Alliances, AstraZeneca														
12.00 – 12.30	Panel Discussion: Avoiding the Cash Drought: Alternative Financing Strategies for Research-Led Companies James Gubbins, Partner, Morrison & Foerster Ken Macleod, Partner, Paul Capital Partners Richard Moulson, CFO, ETV Capital Partners														
13.30 - 15.30	Company Showcase:														
	<table border="0"> <tr> <td>Glide Pharma, Simon Jones, CFO</td> <td>G-Nostics, Mark Tucker, CEO</td> </tr> <tr> <td>Bioceramic Therapeutics, Ian Brown, title</td> <td>Oxford Contrast Molecular Diagnostics, Richard Jones, CEO</td> </tr> <tr> <td>Vivacta, Neil Butler, CEO</td> <td>Orthox, Nick Skaer, CEO</td> </tr> <tr> <td>Orthox, Nick Skaer, CEO</td> <td>OrganOx, Les Russell, CEO</td> </tr> <tr> <td>Glysure, Chris Jones, CEO</td> <td>Oxford Immunotec, Peter Wrighton Smith, CEO</td> </tr> <tr> <td>Advanced Proteome Therapeutics, Alexander Kranz, CEO</td> <td>Domainex, Ed Littler, CEO</td> </tr> <tr> <td></td> <td>Polytherics, Sally Waterman, COO</td> </tr> </table>	Glide Pharma , Simon Jones, CFO	G-Nostics , Mark Tucker, CEO	Bioceramic Therapeutics , Ian Brown, title	Oxford Contrast Molecular Diagnostics , Richard Jones, CEO	Vivacta , Neil Butler, CEO	Orthox , Nick Skaer, CEO	Orthox , Nick Skaer, CEO	OrganOx , Les Russell, CEO	Glysure , Chris Jones, CEO	Oxford Immunotec , Peter Wrighton Smith, CEO	Advanced Proteome Therapeutics , Alexander Kranz, CEO	Domainex , Ed Littler, CEO		Polytherics , Sally Waterman, COO
Glide Pharma , Simon Jones, CFO	G-Nostics , Mark Tucker, CEO														
Bioceramic Therapeutics , Ian Brown, title	Oxford Contrast Molecular Diagnostics , Richard Jones, CEO														
Vivacta , Neil Butler, CEO	Orthox , Nick Skaer, CEO														
Orthox , Nick Skaer, CEO	OrganOx , Les Russell, CEO														
Glysure , Chris Jones, CEO	Oxford Immunotec , Peter Wrighton Smith, CEO														
Advanced Proteome Therapeutics , Alexander Kranz, CEO	Domainex , Ed Littler, CEO														
	Polytherics , Sally Waterman, COO														

Workshops	
Wednesday, 14th April 2010	
12.00–12.30	Current legal issues for life sciences companies Manches LLP , hosted by Jim Kinnier Wilson, Partner Head of Life Sciences
13.30–14.30	Available
14.30–15.00	Planning for Recovery – the Remuneration Issues Biotech Personnel , hosted by Rod Cook, Partner; Andy Christie, Hewitt New Bridge Street
15.30–16.30	Available

Partnering
The gold standard partnering system enables you to select companies and arrange one-to-one meetings. Accepted meetings are then scheduled in private rooms or booths in the Berkshire Stand on:
13th April 2010: 08.30 – 17.00 hrs **14th April 2010: 08.30 – 16.30 hrs**
Partnering system provided by **partneringONE™**

*correct at time of print

About BioTrinity 2010

BioTrinity 2010 is UK's Premier Biopartnering and Investment conference and is building on its reputation as Europe's fastest growing partnering conference with **more investors than any other UK conference**, being the largest UK-focussed biobusiness conference.

This annual conference attracts a multitude of investors, global pharma and innovative R&D companies all within an hour of Heathrow. Using the gold standard on-line partnering system for the life science industry, provided by partneringONE®, delegates can request to meet a range of companies across the sector and once agreed, all meetings are scheduled in private rooms and booths, a feature unique to BioTrinity.

BioTrinity panel sessions feature senior licensing professionals from global pharma, VC's and Investment Banks and will cover the choices for financing and exits for biotech companies, whether that be VC/equity financing, licensing deals or pharma acquisition. Handpicked company presentations showcase the UK's best biotech and medtech companies and high level interactive workshops will give you up to date industry advice and trends. There are plenty of opportunities for informal networking at the networking hubs within the industry exhibition and the vibrant social events programme.

What delegates say about BioTrinity

"BioTrinity has grown every year: from 0 to 140mph in only a few short years. I see it as the central forum for the Biosciences to meet and talk about interesting progressions within the industry"

Matthew Walls, CEO, Epistem

"BioTrinity is an excellent opportunity for our continental EU based fund to meet UK based innovative companies and VC colleagues."

Olivier Litzka, Edmond de Rothschild Investment Partners

"The calibre of attendees from investors, through to large and small biotech and pharma companies was outstanding."

Mark Payton, Fund Principal, Mercia Fund

Who will you meet at BioTrinity?


- UK's best biotech and medtech companies
- More investors than any other UK conference
- Largest number of global pharma licensing executives yet
- The largest gathering of the UK bioindustry

Why attend?

- 83% of delegates rated BioTrinity 2009 as Excellent or Good.
- 85% of delegates had their objectives completely or mostly met.
- 86% of delegates rated the One-to-One partnering at BioTrinity as Excellent or Good.

2009 Statistics:

- 500+ delegates from 16 countries
- 750 partnering meetings (up 50%)
- 40 investment firms from 6 countries
- Two-thirds of top 20 global pharma



Partnering

- Pre-arranged one-to-one meetings in private booths with 650 executives



Presentations

- 32 corporate presentations from a hand-picked list of the best UK life science companies




Workshops

- Interactive workshops on the latest industry trends and advice



Panels

- Global pharma and investors discuss financing, licensing and acquisition strategies



Exhibition

- High traffic exhibition incorporating informal networking hubs



Networking

- Grand Opening Reception, Investor-only tasting dinner, Gala Dinner, Golf tournament

Registration Fees

Standard Registration fee (after 12 February) **£599 + VAT**

On-site registration fee (after 12 April) **£700 + VAT**

Register on-line at www.biotrinity.com

Exhibiting and Sponsorship

Sponsorship and Exhibition opportunities are available for companies seeking maximum exposure. We can develop a package of benefits tailored to meet your company needs and budget. Contact Hilary Boardman to discuss your ideas.

BioTrinity 2010 highlights

- **60+ investor firms expected to attend**
- **75% of world's top global pharma companies**
- **2 full days of one-to-one partnering**

Companies confirmed at time of print

PHARMA

AstraZenca
Boehringer Ingelheim
Bristol Myers Squibb
Daiichi Sankyo Europe GmbH
Genzyme
GSK
Merck
Novartis
OSI Pharmaceuticals
Ranbaxy Labs
Pfizer
Shire Pharma
Takeda Global R&D Centre
Teva Pharmaceutical Industries

INVESTORS

Abingworth
Advent Ventures
Aescap Venture Management BV
Albion Ventures
Alta Partners
Atlas Venture
Beringea
BioGeneration Ventures
ECl Partners
Edmond de Rothschild Investment Partners
Entrepreneurs Fund
ETV Capital
Evolution Securities
Execution Noble
Forbion Capital Partners
IP Group
IPSO Ventures
IQ Capital
Kurma Life Sciences Partner
MedImmune Ventures
Mercia Fund Management
MVM Life Science Partners
Nomura Code Securities
Novo A/S
OSI Investment Holdings
Oxford Capital Partners
Oxford Technology Management
Paul Capital Partners
Piper Jaffray
Quest for Growth
Rainbow Seed Fund
Rosetta Capital
Seroba-Kernel Life Sciences
Singer Capital Markets
Sofinnova Partners
SPARK Venture Management Holdings
SR One
Takeda Research Investment
Technikos
Versant EuroVentures

Aberystwyth University
Adaptimmune
Advanced Proteome Therapeutics Inc.
Alliance Pharmaceuticals
All Phase Clinical Research, Inc
Almac
Aptuit, Inc.
ATPBio
Axela, Inc
BASi
Basinc
BigDNA
Bio2Business
Bioceramic Therapeutics
Bioedge Pharma Consultancy
BioFocus DPI
BioPark
Biotec Services International
Biotech Personnel
BioVex
Boult Wade Tennant
Carbogen Amcis
Canadian Trade Mission
Catalent Pharma Solutions
CellCentric
CellCoTec
CellVax
Charles River Laboratories
Chroma Therapeutics
Communication Strategy Group, Inc.
Covance Laboratories
Cryo-Store
Cyprotex
D2M
Domainex
De Facto Communications
Drug Discovery Today
Defined Health
DSM Biologics
EBD Group
ELGA Process Water
Epistem
ERBI
Essen Instruments
Eurogentec Biologics
Eviva Pharma
Evotec (UK) Ltd
Fermentas
Field Fisher Waterhouse LLP
Fisher Scientific
Focus
Forresters
Frank B. Dehn & Co
Fry Heath Spence
Fulcrum Pharma Europe
Gen-Probe Life Sciences Ltd
George James
Giles Insurance Brokers Limited
Glide Pharma

GlycoMar
G-Nostics
Golden Triangle Partnership
GrantaBio LLP
Health Protection Agency
High Commission of Canada
High Force Research
Hypha Discovery
Immatics Biotechnologies GmbH
Immunocore
Inhibox
Innova Biosciences
Interea International
Intertek ASG
IP Pragmatics
Isis Innovation
JA Kemp & Co
JamesCowper
Karus Therapeutics
KBC Peel Hunt
KWS Biotest
Labcold
Lab Support
LBN
LCG Bioscience
Leads To Development
London Genetics
LTN
Manches
McEwen Labs
Medical Research Council
MEPC
Meridian Life Science, Inc.
Mewburn Ellis LLP
Miami Mice Research Inc
Molecular Profiles
Morrison & Foerster (UK) LLP
MP Bio
M-Scan
Novamass
O2H
OctoPlus N.V.
OrganOx
OBN
Omnicare Clinical Research
One 2 One Global Pharmaceutical Services
Ontario, Canada Biotech Delegation
Oracle
Orthox
Oxagen
Oxford Brookes University School of Life Sciences
Oxford Brookes University Research and Business Development Office
Oxford Contrast Molecular Diagnostics
Oxford Expression Technologies
Oxford Immunotec
Oxford Nanopore Technologies

Oxford Science Park
Oxfordshire County Council
Parexel International
Partnering Excellence
Patheon UK Limited
Peakdale Molecular
PGXIS
Pharma Business Solutions
Pharma Clinical AG
Pharmalicensing
PharmaNet
Pharmidex Pharmaceutical Services
Pharm-Olam International
Pharmatic
PharmaTV
PharmaVentures
Physiomics plc
Piramal Healthcare
PiR Interims
Pivotal Scientific
PlantForm Corporation
Premier Research
Pro-Cure Therapeutics
Prosonix
Proximagen
PsyRING
PULSE Scientific
QuickSTAT
Quotient Bio Research
Randox Laboratories
Reed Scientific
Regulatory Resources Group
Riverbank IT Management
Rouse Patents
RSA Interims
RSSL Pharma
Safeguard Biosystems
Saretius
Saturn Biosciences
Science Warehouse
SCM Pharma
Shasun Pharma Solutions
Silicos NV
Simbec Research
Solid Form Solutions
Solvias AG
SRA Global Clinical Development
SRCL
SRG
Summit plc
Sygnature Chemical Services
Synairgen Research
Syntagon
Syntaxin
Technomark Life Sciences
Thames Valley Innovation and Growth Team
Therabel Europe
Thornhill Research, Inc

Transcrip Partners LLP
TransPerfect Trial Interactive
Ubichem
UCB
UMIP
University of Birmingham
University of Southampton
Vantia
Vernalis plc
Vivacta
VWR International
World Courier
Xention Limited